Exagen (XGN) Resumen de Acciones
Exagen Inc. diseña, desarrolla y comercializa diversos productos de análisis bajo la marca AVISE en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
XGN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Exagen Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$6.70 |
| Máximo en las últimas 52 semanas | US$12.23 |
| Mínimo de 52 semanas | US$2.59 |
| Beta | 2.03 |
| Cambio en 1 mes | 52.62% |
| Variación en 3 meses | 79.62% |
| Cambio de 1 año | -31.28% |
| Variación en 3 años | 161.72% |
| Variación en 5 años | -50.92% |
| Variación desde la OPV | -63.94% |
Noticias y actualizaciones recientes
Artículo de análisis • Aug 07
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Exagen Inc. ( NASDAQ:XGN ) just released its latest quarterly results and things are looking bullish. Exagen...Seeking Alpha • Aug 05
Exagen: The Path To Profitability Just Became More Credible
Summary Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity. Despite a 38% post-earnings rally, I maintain a Buy rating, targeting 62% upside by 2028 as the business' fundamental improvements gain market recognition. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 05
XGN: Autoimmune Test Adoption And 2026 Guidance Will Support Future Upside
Analysts have lifted their price target on Exagen to about $9.71 from roughly $8.67, reflecting updated assumptions around revenue growth, margins and future P/E as they weigh recent coverage highlighting the company's autoimmune testing portfolio and its runway for further market penetration. Analyst Commentary Recent research coverage on Exagen highlights a mix of optimism around its autoimmune testing portfolio and some caution on execution and valuation.Recent updates
Artículo de análisis • Aug 07
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Exagen Inc. ( NASDAQ:XGN ) just released its latest quarterly results and things are looking bullish. Exagen...Seeking Alpha • Aug 05
Exagen: The Path To Profitability Just Became More Credible
Summary Exagen delivered a standout quarter, with 16% revenue growth, record ASP, and near-breakeven adjusted EBITDA, reinforcing the turnaround thesis. XGN raised full-year revenue guidance to $72-75M, with Pharma Services revenue tripling and backlog growing, highlighting new long-term growth levers. Operating margin improved to -8.6%, and Q2 cash generation turned positive, signaling tangible progress toward profitability and improved liquidity. Despite a 38% post-earnings rally, I maintain a Buy rating, targeting 62% upside by 2028 as the business' fundamental improvements gain market recognition. Read the full article on Seeking AlphaActualización de narrativa • Aug 05
XGN: Autoimmune Test Adoption And 2026 Guidance Will Support Future Upside
Analysts have lifted their price target on Exagen to about $9.71 from roughly $8.67, reflecting updated assumptions around revenue growth, margins and future P/E as they weigh recent coverage highlighting the company's autoimmune testing portfolio and its runway for further market penetration. Analyst Commentary Recent research coverage on Exagen highlights a mix of optimism around its autoimmune testing portfolio and some caution on execution and valuation.
Actualización de narrativa • Jul 16
XGN: Market Penetration Execution Will Shape Future Upside Potential
Exagen's analyst price target has been reset from $18.00 to $10.00, as analysts factor in a higher discount rate, more moderate revenue growth assumptions, and a sharply lower future P/E multiple, while still highlighting AVISE CTD's outperformance and early market penetration in recent research. Analyst Commentary Recent Street research on Exagen centers on how analysts weigh the company’s autoimmune testing portfolio, especially AVISE CTD, against the updated valuation framework reflected in the new price target.
Actualización de narrativa • Jul 02
XGN: Early Autoimmune Test Adoption Will Shape Execution-Driven Upside Potential
The analyst fair value estimate for Exagen has shifted from $12.00 to $8.00. The lower target is linked to updated assumptions on growth, profitability, and valuation multiples, while recent Street research highlights analysts' focus on the company's AVISE CTD testing performance and market penetration potential.Actualización de narrativa • Jun 17
XGN: 2026 Guidance And Earnings Focus Will Support Stock Upside
Exagen's latest Narrative Update reflects a modest reduction in the analyst price target, with analysts pointing to slightly adjusted assumptions around discount rate, long term profit margin and future P/E as key drivers of the change in their dollar-denominated valuation framework. Analyst Commentary on Exagen Recent Street research on Exagen focuses on the trimmed price targets and the assumptions that sit behind those moves.Actualización de narrativa • Jun 03
XGN: Volume Momentum And 2026 Guidance Are Expected To Support Upside
Analysts have trimmed their consolidated Exagen price target to $9, down $1 from the prior $10 level, citing softer realized pricing, slower near term gross margin expansion, and more cautious longer term revenue assumptions, while still maintaining generally constructive views on volume trends and reimbursement expertise. Analyst Commentary Recent research updates cluster around a common theme, with analysts trimming Exagen's price targets while still seeing room for execution on volume, reimbursement, and longer term profitability.Artículo de análisis • May 14
Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Exagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...Actualización de narrativa • Apr 24
XGN: Volume Strength And 2026 Guidance Should Support Future Share Gains
Narrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.Actualización de narrativa • Apr 10
XGN: Shares Should Rise As Volumes Offset Transitory Pricing Headwinds
Analysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.Actualización de narrativa • Mar 26
XGN: Shares Should Rise As Volumes Support Long Term Margin Recovery
Analysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.Actualización de narrativa • Mar 12
XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing Headwinds
The analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.Actualización de narrativa • Feb 11
XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish Outlook
Narrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.Actualización de narrativa • Jan 27
XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen Outlook
Analysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.Artículo de análisis • Jan 14
Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%
Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...Actualización de narrativa • Jan 12
XGN: Shares Will Rise As 2025 Guidance Supports Profitability Milestone
The updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.Actualización de narrativa • Dec 21
XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability Prospects
Analysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.Artículo de análisis • Dec 18
Is Exagen (NASDAQ:XGN) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Actualización de narrativa • Dec 07
XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside Potential
Analysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.Actualización de narrativa • Nov 22
XGN: Shares Will Gain As Buy Ratings Signal 50% Upside Potential
Analysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.Artículo de análisis • Nov 18
The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Nov 07
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43
It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...Actualización de narrativa • Nov 06
XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside Potential
Analysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.Actualización de narrativa • Oct 23
Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic Portfolio
Analysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.Artículo de análisis • Aug 05
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
NasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...Artículo de análisis • Aug 01
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...Artículo de análisis • May 18
Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The Industry
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...Artículo de análisis • May 09
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75
As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...Seeking Alpha • Apr 26
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Summary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alpha
Nueva narrativa • Apr 09
Biomarker Launch And AVISE CTD Expansion Will Drive Future Success
New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.Artículo de análisis • Apr 03
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price Rise
The Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...Artículo de análisis • Mar 04
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Feb 05
Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Exagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...Artículo de análisis • Dec 22
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...Artículo de análisis • Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified
Despite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...Artículo de análisis • Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report
Exagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...Artículo de análisis • Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price
You may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...Artículo de análisis • May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge
Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report
Exagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...Artículo de análisis • Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry
With a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...Seeking Alpha • Oct 17
Exagen appoints John Aballi as CEO
Exagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.Rentabilidad de los accionistas
| XGN | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | 0.6% | 0.1% |
| 1Y | -31.3% | 37.2% | 18.9% |
Rentabilidad vs. Industria: Los resultados de XGN fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 37.2% el año pasado.
Rentabilidad vs. Mercado: XGN obtuvo unos resultados inferiores a los del mercado US, que fueron del 18.9% el año pasado.
Volatilidad de los precios
| XGN volatility | |
|---|---|
| XGN Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de XGN ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de XGN(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2002 | 218 | John Aballi | www.exagen.com |
Exagen Inc. diseña, desarrolla y comercializa diversos productos de análisis bajo la marca AVISE en Estados Unidos. La empresa permite a los profesionales sanitarios atender a los pacientes mediante el diagnóstico, el pronóstico y el seguimiento de enfermedades reumáticas complejas, autoinmunes y relacionadas con la autoinmunidad, como el lupus eritematoso sistémico (LES) y la artritis reumatoide (AR). El principal producto analítico de la empresa es AVISE CTD, que permite el diagnóstico diferencial de pacientes que presentan síntomas indicativos de diversas enfermedades del tejido conjuntivo (CTD) y otras enfermedades relacionadas con síntomas que se solapan.
Resumen de fundamentos de Exagen Inc.
| Estadísticas fundamentales de XGN | |
|---|---|
| Capitalización bursátil | US$161.34m |
| Beneficios(TTM) | -US$18.92m |
| Ingresos (TTM) | US$71.12m |
2.3x
Ratio precio-ventas (PS)-8.6x
Ratio precio-beneficio (PE)¿Está XGN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de XGN | |
|---|---|
| Ingresos | US$71.12m |
| Coste de los ingresos | US$29.42m |
| Beneficio bruto | US$41.70m |
| Otros gastos | US$60.63m |
| Beneficios | -US$18.92m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.78 |
| Margen bruto | 58.64% |
| Margen de beneficio neto | -26.61% |
| Ratio deuda/patrimonio | 187.0% |
¿Cómo se ha desempeñado XGN a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/17 15:37 |
| Precio de las acciones al final del día | 2026/08/17 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Exagen Inc. está cubierta por 8 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |